

Prevalence of Cardiometabolic Disease Risk Factors in People living with HIV Initiating Anti-retroviral Therapy at a High-Volume HIV Clinic in Kampala, Uganda

Willington Amutuhaire¹, Frank Mulindwa^{2,3}, Barbara Castelnuovo², Nele Brusselaers^{3,4}, Jean-Marc Schwarz⁵, Mutebi Edrisa, Simon Dujanga⁶, Robert A. Salata^{1,7}, George A. Yendewa^{1,7*}

- 1 Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- 2 Makerere University Infectious Diseases Institute, Kampala, Uganda.
- 3 Global Health Institute, Antwerp University, Antwerp, Belgium.
- 4 Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
- 5 School of Medicine, University of California San Francisco, USA.
- 6 Kisenyi Health Center, HIV clinic, Kampala, Uganda.
- 7 Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

Key words: HIV, metabolic syndrome, ART, Uganda

Key points: In Ugandan HIV patients initiating antiretroviral treatment, the prevalence of cardiometabolic risk factors was substantial: metabolic syndrome 13.9%, dyslipidemia 93.6%, abdominal obesity 34.0%, hyperglycemia 18.4%, and hypertension 8.1%. This highlights the need for early screening and management of comorbidities.

*** Corresponding author:**

George A. Yendewa, MD, MPH&TM, FACP, FIDSA
Assistant Professor of Medicine (Infectious Diseases)
Case Reserve Western University School of Medicine
Division of Infectious Diseases and HIV Medicine
University Hospitals Cleveland Medical Center
11100 Euclid Ave, Cleveland, OH 44106, USA
Telephone: +1 216-844-1988
Fax: +1 216-844-1632
E-mail: gay7@case.edu

Alternate corresponding author:

Willington Amutuhaire, MD, MPH
Department of Medicine
Division of Infectious Diseases and HIV Medicine
University Hospitals Cleveland Medical Center
11100 Euclid Ave, Cleveland, OH 44106, USA
Telephone: +1 216-844-1988
Email: willington.amutuhaire@uhhospitals.org

ABSTRACT

Background: Cardiometabolic diseases are a leading cause of HIV-related morbidity and mortality, yet routine screening is not undertaken in high burden countries. We aimed to assess the prevalence and risk factors of the metabolic syndrome (MetS) and its components in adult Ugandan people living with HIV (PLHIV) initiating dolutegravir-based antiretroviral therapy (ART).

Methods: We analyzed baseline data of PLHIV aged ≥ 18 years enrolled in the GLUMED (Glucose metabolism changes in Ugandan HIV patients on Dolutegravir) Study from January to October 2021. MetS was defined as having 3 or more of the following: abdominal obesity, hypertension (HTN), elevated fasting glucose, elevated triglycerides and low high-density lipoprotein cholesterol. Multiple logistic regression was used to assess associations between potential risk factors and MetS and its components.

Results: 309 PLHIV were analyzed (100% ART-naive, 59.2% female, median age 31 years and median CD4 count 318 cells/mm³). The prevalence of MetS was 13.9%. The most common cardiometabolic condition was dyslipidemia (93.6%), followed by abdominal obesity (34.0%), hyperglycemia (18.4%), and HTN (8.1%). In adjusted analysis, MetS was associated with age > 40 years (odds ratio 3.33, 95% confidence interval 1.45-7.67) and CD4 count > 200 cells/mm³ (3.79, 1.23-11.63). HTN was associated with age > 40 years (2.96, 1.32-6.64), and dyslipidemia was associated with urban residence (4.99, 1.35-18.53).

Conclusion: Cardiometabolic risk factors were common in this young Ugandan cohort of PLHIV initiating dolutegravir-based ART, underscoring the need for programmatic implementation of surveillance and management of comorbidities in Uganda and similar settings.

BACKGROUND

The HIV epidemic remains a major public health problem, with 38 million people infected globally in 2021[1]. Despite this, increased access to potent combination anti-retroviral therapy (ART) has substantially lowered HIV-related morbidity and mortality and prolonged the life expectancy of people living with HIV (PLHIV). This is of utmost relevance in sub-Saharan Africa (SSA) where the global burden of HIV is highest[2], [3]. Paradoxically, this has resulted in an increase in the burden of non-communicable diseases (NCDs) among PLHIV[3]–[6]. Globally, NCDs cause 41 million deaths annually, with cardiovascular diseases (CVDs) accounting for nearly half (44%) of such deaths[7]. PLHIV are at a two-fold higher risk of experiencing myocardial infarction, strokes and other CVDs due to multiple factors, including having a higher prevalence of traditional CVD risk factors at baseline, ART-associated toxicities, HIV-induced immune activation and chronic systemic inflammation[8], [9]. With recent modelling studies projecting an excess increase in NCDs among PLHIV[10], [11], the Joint United Nations Programme on HIV/AIDS (UNAIDS) is advocating for increased surveillance and integration of NCD care in HIV programs[12]–[14].

Since 2016, the World Health Organization (WHO) has recommended the use of integrase strand transfer inhibitors (INSTI) as the preferred first- and second-line ART[15], [16]. This followed multiple reports of increasing primary HIV drug resistance (HIVDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs), with many high burden countries reporting NNRTI HIVDR prevalence rates exceeding the 10% recommended threshold[17], [18]. Subsequently, most countries in SSA have moved to adopt dolutegravir (DTG)-based regimens as first-line ART, due to its high barrier to resistance, tolerability, and less drug-drug interactions [19]–[21]. Despite their tolerability, however, INSTIs have consistently been linked to excessive weight gain, particularly among women, older patients, and people of Black or African ancestry[22]–[24]. Additionally, analyses for insulin resistance trajectories from multiple clinical trial data, e.g., SPRING-2 [23], SAILING [24], and VIKING-3 described worsening insulin resistance in patients post switch to INSTI-based ART[25]. Similarly, multiple case reports describing real world experiences with INSTI use have documented accelerated hyperglycemia in patients post switch to INSTI-based ART [26]–[28]. In one such a report from Uganda, there was an observed incidence rate of 4.7 cases of hyperglycemia per 1000 patients in a median duration of 4 months after initiating DTG-based ART, with the majority (15 of 16 cases) presenting with diabetic ketoacidosis[26]. Consequently, the Ugandan Ministry of Health HIV treatment guidelines halted the use of DTG in patients known to have diabetes or at high risk of cardiometabolic diseases[29], [30].

Given the well described metabolic complications associated with INSTIs, their widespread adoption as first- and second-line ART in SSA is likely to significantly exacerbate the growing problem of NCDs among PLHIV in this region. It is therefore essential that HIV treatment programs in SSA implement effective NCD control measures focused on early screening and prevention of comorbidities. However, there are limited studies to inform evidence-based public health policy and clinical practice. In this study, we aimed to assess the prevalence and risk factors associated with the metabolic syndrome (MetS) and its components in a cohort of treatment naïve PLHIV starting ART at a high-volume HIV clinic in Kampala, Uganda.

METHODS

Study design and setting

The GLUMED (Glucose metabolism changes in Ugandan HIV patients on Dolutegravir) Study was a prospective cohort study that enrolled newly diagnosed PLHIV prior to ART initiation between January and September 2021 at Kisenyi Health Center HIV Clinic in Kampala, the capital and largest city in Uganda. The primary objective of the study was to describe changes in glucose metabolism in Ugandan PLHIV at study entry and 48 weeks after initiating DTG-based ART. The Kisenyi Health Center HIV Clinic is one of the busiest in the country, with about 12,000 active PLHIV enrolled in routine care. We analyzed baseline sociodemographic and clinical data on patients who were sequentially enrolled in the study.

Study participants

Between January and October 2021, ART naïve PLHIV aged 18 years or older starting DTG-based ART were screened for study inclusion. HIV status was determined using the rapid test by SD Bioline HIV-1/2 3.0 (Standard Diagnostics Inc, Suwon, Korea). Pregnant women and very sick patients deemed unable to undergo a 2 hour -75g oral glucose tolerance test (OGTT) were excluded. Criteria for exclusion during follow up included: pregnancy, development of T2DM, non-adherence to study protocols and poor adherence to ART.

Of the 435 PWH screened, 310 patients (71%) consented for oral glucose tolerance test evaluation for study enrollment. One patient was lost to follow up, leaving 309 patients that provided data for analysis. ([Figure 1](#))

Study processes

After consenting, patients were scheduled for review in 24 to 48 hours after an overnight fast of 8- 12 hours. Peripheral venous cannulae were placed and 5 ml of fasting venous blood was collected in plain 5ml BD Vacutainers®. Patients were then given 300 ml of 75 gram-glucose solution to be taken within 5 minutes. Repeat 5 ml blood samples were collected at: 30, 60, 90 and 120 minutes from the time of ingestion of the glucose solution. Blood glucose was measured at all time points immediately after sample collection (before transfer to vacutainers) using ACCU-CHECK™ glucometers (Roche Diagnostics, Mannheim, Germany) [31]. After centrifugation of the whole venous blood samples, serum was collected and stored at -80°C for batched serum lipids, creatinine, insulin and C-peptide analysis. Patients found to have a normal 2-hour 75g OGTT (fasting blood glucose <126mg/dl and 2-hour glucose <200mg/dl) were enrolled for 48-week follow up on tenofovir/ lamivudine/ dolutegravir as recommended by the Uganda National HIV treatment guidelines. [32]

Baseline demographic, clinical and social data were collected which included: age, sex, CD4 count (determined by Alere Pima Analyzer (Abbott Diagnostics, Jena, Germany), body mass index (BMI), level of education, area of residence, blood pressure, waist circumference, tuberculosis (TB) status, smoking status, physical activity measured by the Global Physical Activity Questionnaire (GPAQ), alcohol consumption measured by

the Alcohol Use Disorders Identification Test (AUDIT), serum creatine and serum lipid profiles (Cobas 6000® from Roche Diagnostics).

Assessments and variable definitions

Risk of harmful alcohol use was assessed using the standardized AUDIT questionnaire[33]. Level of physical activity was reported as meeting or not meeting the WHO Global physical activity questionnaire (GPAQ) thresholds [30].

Waist circumference (WC) measurements were used to assess abdominal obesity and risk of cardiometabolic disease was stratified according to the WHO criteria[34], as follows: (1) not at risk: < 95 cm (males) and < 81 cm (females); (2) at increased risk: males ≥ 95 to ≤ 102 cm and females ≥ 81 to ≤ 88 cm; and (3) at substantially increased risk: ≥ 103 cm (males) and ≥ 89 cm (females). Body mass index (BMI) was classified based on the CDC[35] as follows (1) underweight: < 18.5 kg/m², (2) normal: 18.5 -24.9 kg/m², (3) overweight: 25-29.9 kg/m², and obese: ≥ 30 kg/m² for obese[35]. Hypertension was assessed as the average of two readings or being on antihypertensive treatment and was categorized in accordance with the Joint National Committee 8 (JNC-8) guidelines[36], as follows: (1) normal: systolic blood pressure (SBP) < 120 mmHg and diastolic blood pressure (DBP) < 80 mmHg; (2) pre-hypertension: SBP 120-139 mmHg or DBP 80-89 mmHg; and (3) hypertension (HTN): SBP ≥ 140 mmHg or DBP ≥ 90 mmHg.

Blood glucose level was categorized in accordance with American Diabetes Association criteria[37], as follows: (1) normal: fasting glucose < 100 mg/dL or 2-hour OGTT < 140 mg/dL; (2) prediabetes: fasting glucose 100-125 mg/dL or 2-hour glucose 140-199 mg/dL; and (3) diabetes: fasting glucose ≥ 126 mg/dL or 2-hour or glucose ≥ 200 mg/dL. Dyslipidemia was defined as having any one of the following[38]: total cholesterol (TC) > 200 mg/dL, high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL (males) or < 50 mg/dL (females), low-density lipoprotein cholesterol (LDL-C) > 100 mg/dL and triglycerides (TG) > 150 mg/dL. Glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease (MDRD) Study equation[39], with renal impairment defined as eGFR < 60 mL/min/1.73 m². Laboratory-based 10-year CVD (Framingham) risk scores were calculated for participants aged ≥ 30 years (170/309 (55%)) and classified as follows: low risk: < 10%, intermediate risk: 10-20% and high risk; >20%[40]. Lastly, we used a harmonized definition of the MetS based on diagnostic criteria proposed by the International Diabetes Federation (IDF) Task Force on Epidemiology and Prevention, the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) and the World Health Organization (WHO)[41], which requires having at least 3 of the following 5 criteria: (1) WC > 94 cm (men) or >81 cm women); (2) TG ≥ 150 mg/dL; (3) HDL-C < 40 mg/dL (males) or < 50 mg/dL(females); (4) fasting glucose ≥ 100 mg//dL; and (5) SBP ≥ 130 mm Hg or DBP ≥ 85 mm Hg.

Statistical analysis

Statistical analyses were performed using SPSS Version 29.0 (Armonk, NY; IBM Corp). Categorical variables were reported as frequencies (percentages) and associations assessed using Pearson's chi-square or Fisher's exact tests. Continuous variables were presented as medians (interquartile ranges, IQR) and associations assessed using the non-parametric independent samples Mann-Whitney U-test. A logistic regression model

was used to identify associations between MetS and each of its components (i.e., HTN, dyslipidemia, and hyperglycemia) and known or potential associated risk factors. Only variables that attained a p-value of < 0.2 in the univariate analysis were included in the multivariate regression model. Associations were reported as crude (OR) and adjusted odds ratios (AOR) with 95% confidence intervals (CI), $p < 0.05$ considered statistically significant.

Patient Consent Statement

Ethical approval to perform the study was obtained from The AIDS Support Organization (TASO) Institutional Review Board (registration number: TASOREC/051/2020-UG-REC-009) and the Uganda National Council for Science and Technology (Registration number: HS1032ES). All participants signed informed consent prior to enrolment in the study.

RESULTS

Baseline characteristics of study participants

A total of 309 PWH were enrolled in the study and the majority (59.2%, 183/309) were female. The median age was 31 years (IQR 27-39), with males being older than females (median ages 34 vs 30 years, $p < 0.001$). Most were single (57.6%, 178/309), had attained primary education or higher (98.7%, 305/309), were Christian (79.3%, 245/309), resided in urban areas (92.2%, 285/309) and were employed (81.9%, 253/309). Of the 259 PWH with available data, the median CD4 count was 318 cells/mm³ (Interquartile range (IQR): 163-550) at enrollment. ([Table 1](#))

Prevalence of cardiometabolic risk factors

The overall proportion of patients with a history of smoking and harmful alcohol use (AUDIT ≥ 16) was low at 4.9% (15/309) and 6.5% (20/309), respectively. The majority (78.0%, 241/309) met the WHO daily goals for physical activity. The median BMI was 22.2 kg/m², with women more likely to have higher median BMIs compared with their male counterparts ($p < 0.001$). Overall, 21.7% (67/309) were classified as overweight (pre-obesity, BMI 25-29.9 kg/m²), while 8.1% (25/309) were classified as obese (BMI ≥ 30 kg/m²). Based on the WC measurements, 18.4% (57/309) of participants were at increased risk cardiometabolic disease, while 15.5% (48/309) were at a substantially higher risk. There were sex differences observed, with women more likely to have higher WC measurements ($p < 0.001$).

A substantial proportion of study participants had prehypertension (16.8%, 52/309), while 8.1% (25/309) had HTN. The prevalence of overt diabetes was low at 0.3% (1/309); however, 18.1% (56/309) had prediabetes. Of those with available testing for kidney function, the median serum creatinine was 0.80 mg/dL, with a small proportion of study participants (1.4%, 4/282) having impaired renal function (eGFR < 60 ml/min/1.73m²).

About 93.6% (264/282) of study participants had dyslipidemia. The prevalence of hypercholesterolemia (TC > 200 mg/dL) was low at 5.3% (15/282). Of the individual components of the lipid panel, 88.3% (249/282) had low HDL-c (HDL-c < 40 mg/dL), 20.9% (59/282) had elevated LDL-c (LDL-c > 100 mg/dL), while 13.1% (37/282) had elevated triglycerides (TG > 150 mg/dL). More women had derangements in the individual fractions of the lipid panel compared with their male counterparts (all $p < 0.001$). Overall, 13.9% (43/309) of study participants met the criteria for the metabolic syndrome, without sex differences ($p=0.129$). Despite this, only a small proportion (1.8%, 3/170) had a 10-year CVD risk > 10%. ([Table 2](#))

Associated Risk Factors of MetS and its components

In adjusted multivariate logistic regression analysis, MetS was significantly associated with age > 40 years (Adjusted Odds Ratio (AOR) 3.33, 95% confidence interval (CI) 1.45-7.67) and CD4 count > 200 cells/mm³ (AOR 3.79, 95% CI 1.23-11.63). Similarly, hypertension was significantly associated with age > 40 years (AOR 2.96, 95% CI 1.32-6.64). Dyslipidemia was predicted by residence in an urban area (AOR 4.99, 95% CI 1.35-18.53); however, there were no independent predictors for hyperglycemia ([Table 3](#)).

DISCUSSION

In this study of treatment-naïve adult PLHIV initiating ART in Uganda, we estimated the baseline prevalence of MetS and key CVD risk factors with the aim of enhancing early screening and timely prevention of NCDs among Ugandan PLHIV. In mixed population studies, HIV-positive status has consistently conferred a higher risk of MetS and its components[42]. This underscores the necessity for pre-emptive screening for MetS both at baseline and prospectively while on ART.

Despite being a relatively young cohort (median age 31 years), the prevalence of MetS was 13.9% (i.e., about 1 in 7 patients) in our study. While several studies have assessed the prevalence of MetS among PLHIV in SSA, few have incorporated metabolic profiling at ART initiation. Estimates of the prevalence of MetS among PLHIV in SSA have generally been reported to be higher than our estimate, ranging from 20% to 58% [42]–[46]. This is likely a reflection of the fact that in most of these studies, participants were older and had a history of exposure to early ART-era protease inhibitors (PIs) and NRTIs, which were associated with higher rates of lipid and glucose dysmetabolism [47]–[50].

Dyslipidemia was the most common CVD risk factor in our cohort, affecting about 93.6% of patients. Of these, low HDL-C was by far the most important risk factor and was present in 88.6% (or nearly 9 in 10 patients). Few studies from SSA have documented the lipid profile of PLHIV pre-ART; most reports have focused largely on ART-exposed individuals. In five cross-sectional studies of ART-exposed PLHIV from Malawi, Nigeria, Ethiopia and Cameroon, the prevalence of low HDL-C, elevated LDL-C, TG and TC were 34-63%, 17-21%, 9% and 11-24%, respectively, which were lower than our findings [51]–[54]. In these and other studies from SSA, advanced age, duration on ART, increased waist-to-hip ratio, high BMI and a sedentary lifestyle have been identified as risk factors of dyslipidemia [51]–[59]. We did not detect any statistically significant associations

between these traditional risk factors and dyslipidemia in our cohort; however urban residence conferred a 5-fold higher risk of dyslipidemia. Plausible explanations for this finding include a higher prevalence of traditional CVD risk factors among urban dwellers compared to their rural counterparts such as such as unhealthy dietary habits, a more sedentary lifestyle and greater levels of exposure to environmental pollutants among urban dwellers (e.g., emissions from fossil fuel combustion and industrial processes). Careful studies are needed to confirm these hypotheses.

Hypertension is a common comorbidity among PLHIV and was estimated to affect 24% of PLHIV globally in recent meta-analysis by Bigna *et al* [60]. In this and other studies, geographic variations in the prevalence of hypertension among PLHIV have been reported, with countries in SSA being disproportionately affected [61]-[67]. Despite the prevalence of hypertension being lower in our study (8.1%), a substantial proportion (17%) were pre-hypertensive and at risk of progressing to hypertension. Similarly, the prevalence of diabetes mellitus in our study was very low (0.3%), while pre-diabetes was higher (18.1%). The link between diabetes and HIV is controversial, with some studies suggesting that HIV is an independent risk factor of diabetes [68], [69], while others have failed to establish a clear link [70], [71]. However, as previously discussed, PLHIV exposed to ART (especially INTSI-based regimens) are at risk of metabolic complications including weight gain, increased insulin resistance and the metabolic syndrome [22]-[30]. Thus, the identification of pre-hypertension and prediabetes prior to ART exposure offers opportunities to intervene early with non-pharmacological risk-reduction strategies (e.g., smoking cessation, increased physical exercise, weight loss and reduced salt-intake) to lower overall CVD risk.

Of the traditional CVD risk factors that were assessed in our study, increasing age (≥ 40 years) and CD4 count (≥ 200 cells/mm³) were associated with a higher risk of both MetS and hypertension, respectively. The latter finding is consistent with previous studies which have shown that higher CD4 cell count is an independent predictor of the development of MetS, attributable largely to the expected improvement in nutritional intake, weight gain and energy conservation associated with initiation ART [72]-[74]. However, our cohort was entirely ART-naïve. It remains unclear what mechanisms are at play linking degree of immunosuppression and CVD risk stratification in ART-naïve patients. Further studies are needed to explore the potential underlying causes of this finding.

We used laboratory-based Framingham scores to estimate 10-year CVD risk for study participants above 30 years (50% of enrolled participants) and determined that the majority had low 10-year CVD risk. In three studies from Cameroon and South Africa, 50 to 93% of PLHIV had a 10-year CVD risk of $< 5\%$ [75]-[77], compared with 87% of patients in our study. Most CVD risk calculators, including the Framingham score that we used in our study tend to underestimate the 10-year CVD risk, as they do not take into account other patient characteristics such as the inherent effect of HIV itself, systemic inflammation, as well as infectious and non-communicable comorbidities [78]. This may explain the possible underestimation of risk in the cited studies above, involving much older patients on ART, a known risk factor to both micro- and macro-vascular disease [47]. Despite the reported low 10-year risk of CVD in our study population, we demonstrated that this is a population with high frequencies of individual CVD risk factors, and therefore hypothesize that their actual CVD risk may be much higher than the calculated risk.

Another noteworthy finding of our study was that although women had a higher prevalence of individual CVD risk factors (e.g., higher BMI, waist circumference, higher LDL and TG) compared with their male counterparts, there was no sex difference in the overall prevalence of MetS. Sex differences are known to influence the occurrence of MetS across different age groups in the general population [79]. A large part of this difference is attributable to the cardioprotective effects of estrogen and other hormones on glucose and lipid metabolism in women [79] [75]; the reduction in hormonal influence in post-menopausal women is implicated in the observed increase in seen the prevalence MetS and CVD risk in age-matched controls [79] [75]. Similar to our study, most studies which have reported on the prevalence of MetS in SSA have been in ART-exposed PLHIV and have not shown a sex differential effect [44], [80].

Our study had several limitations worthy of discussion. Firstly, the definition of MetS and its key components are based on models developed in high income countries and may not be applicable to populations in SSA, which may exhibit significant phenotypic and genotypic differences. Secondly, this was a single center study in an urban setting, hence the findings may not be generalizable to the wider Ugandan PLHIV population. Thirdly, based on study inclusion criteria, sicker patients were excluded due to their inability to undergo a 2-hour OGTT, which would have resulted in under-estimation of the prevalence of MetS and its components. Despite these limitations, while most studies have described prevalence rates of CVD risk factors in PLHIV on ART, our study described the metabolic profiles of ART-naïve Ugandan PLHIV at ART initiation, thus offering an opportunity to improve prevention strategies in a population with a high CVD risk.

CONCLUSION

We demonstrated that despite being a relatively young population, cardiometabolic risk factors were common among Ugandan PLHIV initiating DTG-based ART, underscoring the need for programmatic implementation of surveillance and management of NCD comorbidities among PLHIV initiating ART in Uganda and similar settings.

DECLARATIONS

Ethics approval and consent to participate

Ethical approval to perform the study was obtained from The AIDS Support Organization (TASO) Institutional Review Board (registration number: TASOREC/051/2020-UG-REC-009) and the Uganda National Council for Science and technology (Registration number: HS1032ES). All participants signed informed consent prior to enrolment in the study.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Potential Conflicts of Interest

All authors declare no competing interests

Funding

The study received funding support from NIH-Fogarty University of California (UCSF) Global Health Fellowship Program, grant number: 2D43TW009343-06 (F.M., J-M.S.), the National Institutes of Health, UCSF-Gladstone Center for AIDS Research, grant number: P30AI027763 (F.M., J-M.S.) and the Fogarty International Center of the National Institutes of Health, Award Number D43TW009771 (B.C.). Additional funding were provided through the Roe Green Center for Travel Medicine and Global Health/University Hospitals Cleveland Medical Center (W.A., G.A.Y.).

Authors' contributions

Conceptualization: W.A., F.M., G.A.Y. Methodology: W.A., F.M., G.A.Y. Resources: F.M., B.C., N.B., S.D., M.E., J-M.S. Formal analysis: G.A.Y. Investigation: W.A., F.M., M.E., S.D. Visualization: W.A., F.M., G.A.Y. Writing—original draft preparation: W.A., F.M., G.A.Y. Writing—review and editing: W.A., F.M., B.C., N.B., J-M.S., M.E., S.D., R.A.S., G.A.Y. Funding acquisition: W.A., F.M., B.C., N.B., J-M.S., G.A.Y. All authors contributed important intellectual content and participated in the interpretation of results, writing and editing of the final manuscript draft.

Acknowledgments

We acknowledge the Makerere University Infectious Diseases Institute and the Kampala City Council Authority (KCCA) for permitting us to use the Kisenyi HIV clinic for the study. we also acknowledge the administrative support from the Kisenyi Health Center IV administration. Lastly, we acknowledge the patients that participated in our study.

References

- [1] “Global HIV & AIDS statistics — Fact sheet | UNAIDS.” <https://www.unaids.org/en/resources/fact-sheet> (accessed Jan. 06, 2023).
- [2] “Yes, the same life expectancy as HIV-negative people, but far fewer years in good health | aidsmap.” <https://www.aidsmap.com/news/mar-2020/yes-same-life-expectancy-hiv-negative-people-far-fewer-years-good-health> (accessed Jul. 30, 2022).
- [3] N. A. Jespersen, F. Axelsen, J. Dollerup, M. Nørgaard, and C. S. Larsen, “The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era,” *HIV Med.*, vol. 22, no. 6, pp. 478–490, Jul. 2021, doi: 10.1111/HIV.13077.
- [4] Unaid, “Responding to the Challenge of Non-communicable Diseases,” doi: 10.1097/QAD.0000000000001888.
- [5] “PROCEDURE FOR GLUCOSE TOLERANCE TEST | REGIONAL MEDICAL LABORATORY.” <https://www.rmlonline.com/site/sections/53> (accessed Apr. 09, 2020).
- [6] D. Achwoka, R. Mutave, J. O. Oyugi, and T. Achia, “Tackling an emerging epidemic: the burden of non-communicable diseases among people living with HIV/AIDS in sub-Saharan Africa,” *Pan Afr. Med. J.*, vol. 36, no. 271, pp. 1–9, May 2020, doi: 10.11604/PAMJ.2020.36.271.22810.
- [7] “Noncommunicable diseases.” <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases> (accessed Jan. 06, 2023).
- [8] “Cardiac and vascular disease in patients with HIV - UpToDate.” <https://www.uptodate.com/contents/cardiac-and-vascular-disease-in-patients-with-hiv> (accessed Jan. 06, 2023).
- [9] K. So-Armah *et al.*, “HIV and cardiovascular disease,” *Lancet HIV*, vol. 7, no. 4, pp. e279–e293, Apr. 2020, doi: 10.1016/S2352-3018(20)30036-9.
- [10] M. Smit *et al.*, “Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study,” *PLoS One*, vol. 12, no. 10, p. e0186638, Oct. 2017, doi: 10.1371/JOURNAL.PONE.0186638.
- [11] M. Smit *et al.*, “Mapping the Current and Future Noncommunicable Disease Burden in Kenya by Human Immunodeficiency Virus Status: A Modeling Study,” *Clin. Infect. Dis.*, vol. 71, no. 8, pp. 1864–1873, Nov. 2020, doi: 10.1093/CID/CIZ1103.
- [12] “Combining treatment of Non-Communicable Diseases and HIV in Uganda: Novel Study reveals Benefits | LSHTM.” <https://www.lshtm.ac.uk/research/units/mrc-uganda/news/340076/combining-treatment-non-communicable-diseases-and-hiv-uganda-novel-study> (accessed Jan. 06, 2023).
- [13] E. H. Shayo *et al.*, “The acceptability of integrated healthcare services for HIV and non-communicable diseases: experiences from patients and healthcare workers in Tanzania,” *BMC Health Serv. Res.*, vol. 22, no. 1, pp. 1–12, Dec. 2022, doi: 10.1186/S12913-022-08065-4/TABLES/2.
- [14] “Chronic care of HIV and noncommunicable diseases How to leverage the HIV experience,” 2011.

- [15] “WHO recommends dolutegravir as preferred HIV treatment option in all populations.” <https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations> (accessed Jul. 30, 2022).
- [16] “UPDATE OF RECOMMENDATIONS ON FIRST-AND SECOND-LINE ANTIRETROVIRAL REGIMENS,” 2019, Accessed: Jul. 30, 2022. [Online]. Available: <http://apps.who.int/bookorders>.
- [17] “Fact Sheet: HIV Drug Resistance.” <https://www.who.int/news-room/fact-sheets/detail/hiv-drug-resistance> (accessed Oct. 30, 2022).
- [18] D. Frentz *et al.*, “Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe,” *BMC Infect. Dis.*, vol. 14, no. 1, pp. 1–12, Jul. 2014, doi: 10.1186/1471-2334-14-407/FIGURES/2.
- [19] D. E. Dow and J. A. Bartlett, “Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV,” *Infect. Dis. Ther.*, vol. 3, no. 2, pp. 83–102, Dec. 2014, doi: 10.1007/S40121-014-0029-7/FIGURES/2.
- [20] M. D’Abbraccio, A. Busto, M. De Marco, M. Ficoni, A. Maddaloni, and N. Abrescia, “Efficacy and tolerability of integrase inhibitors in antiretroviral-naive patients,” *AIDS Rev.*, vol. 17, no. 3, pp. 171–185, 2015.
- [21] S. L. Karmon and M. Markowitz, “Next-generation integrase inhibitors : where to after raltegravir?,” *Drugs*, vol. 73, no. 3, pp. 213–228, Mar. 2013, doi: 10.1007/S40265-013-0015-5.
- [22] A. R. Eckard and G. A. McComsey, “Weight gain and integrase inhibitors,” *Current Opinion in Infectious Diseases*, vol. 33, no. 1. Lippincott Williams and Wilkins, pp. 10–19, Feb. 01, 2020, doi: 10.1097/QCO.0000000000000616.
- [23] B. R. Wood, “Do Integrase Inhibitors Cause Weight Gain?,” *Clin. Infect. Dis.*, vol. 70, no. 7, pp. 1275–1277, Mar. 2020, doi: 10.1093/CID/CIZ410.
- [24] M. Wendy S. Armstrong, “More Evidence for Weight Gain with Newer-Generation Integrase Inhibitors,” *NEJM J. Watch*, vol. 2021, Mar. 2021, doi: 10.1056/NEJM-JW.NA53234.
- [25] J. van W. Janet Lo, James Oyee, Melissa Crawford, Richard Grove, Ralph DeMasi, Lloyd Curtis, Anna Fettiplace, Vani Vannappagari, Nassrin Payvandi, Michael Aboud4, “Dolutegravir and Insulin resistance,” 2019.
- [26] M. Lamorde *et al.*, “Dolutegravir-associated hyperglycaemia in patients with HIV,” *The Lancet HIV*, vol. 7, no. 7. Elsevier Ltd, pp. e461–e462, Jul. 01, 2020, doi: 10.1016/S2352-3018(20)30042-4.
- [27] M. McLaughlin, S. Walsh, and S. Galvin, “Dolutegravir-induced hyperglycaemia in a patient living with HIV,” *Journal of Antimicrobial Chemotherapy*, vol. 73, no. 1. Oxford University Press, pp. 258–260, Jan. 01, 2018, doi: 10.1093/jac/dkx365.
- [28] N. S. Nolan, S. Adamson, D. Reeds, and J. A. O’Halloran, “Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus,” *Open Forum Infect. Dis.*, vol. 8, no. 5, May 2021, doi: 10.1093/OFID/OFAB077.
- [29] M. O. F. Health, “MINISTRY OF HEALTH CONSOLIDATED GUIDELINES FOR THE PREVENTION AND TREATMENT OF HIV AND AIDS IN UGANDA,” no. February, 2020.

- [30] MoH Uganda, “Uganda HIV treatment guidelines,” 2018.
- [31] E. Eyth, H. Basit, and C. J. Swift, “Glucose Tolerance Test,” *Br. Med. J.*, vol. 2, no. 5145, pp. 191–192, Oct. 2022, doi: 10.1136/bmj.2.5145.191-b.
- [32] “MINISTRY OF HEALTH CONSOLIDATED GUIDELINES FOR THE PREVENTION AND TREATMENT OF HIV AND AIDS IN UGANDA,” 2020.
- [33] L. Malet, I. De Chazeron, R. Schwan, P. M. Llorca, and B. Falissard, “The Alcohol Use Disorders Identification Test (AUDIT) in question [2],” *Encephale*, vol. 31, no. 4 I, pp. 518–519, 2005.
- [34] Geneva, “Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation,” Accessed: Jul. 30, 2022. [Online]. Available: www.who.int.
- [35] “About Adult BMI | Healthy Weight, Nutrition, and Physical Activity | CDC.” https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html (accessed Jul. 30, 2022).
- [36] “JNC 8 Guidelines for the Management of Hypertension in Adults.” <https://www.aafp.org/pubs/afp/issues/2014/1001/p503.html> (accessed Jul. 30, 2022).
- [37] “Diagnosis | ADA.” <https://www.diabetes.org/a1c/diagnosis> (accessed Apr. 09, 2020).
- [38] D. K. Arnett *et al.*, *2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines*, vol. 140, no. 11. 2019.
- [39] “MDRD GFR Equation - MDCalc.” <https://www.mdcalc.com/calc/76/mdrd-gfr-equation> (accessed Jan. 08, 2023).
- [40] “Framingham Risk Calculator | Heart Attack Risk.” <https://www.omnicalculator.com/health/framingham-risk> (accessed Dec. 25, 2022).
- [41] “Consensus statements.” <https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definition-of-the-metabolic-syndrome.html> (accessed Aug. 09, 2021).
- [42] O. O. Todowede, S. Z. Mianda, and B. Sartorius, “Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa - A systematic review and meta-analysis 11 Medical and Health Sciences 1117 Public Health and Health Services,” *Syst. Rev.*, vol. 8, no. 1, pp. 1–17, Jan. 2019, doi: 10.1186/S13643-018-0927-Y/TABLES/6.
- [43] S. Ambachew, A. Endalamaw, A. Worede, Y. Tegegne, M. Melku, and B. Biadgo, “The Prevalence of Metabolic Syndrome in Ethiopian Population: A Systematic Review and Meta-analysis,” *J. Obes.*, vol. 2020, 2020, doi: 10.1155/2020/2701309.
- [44] C. N. Kiama *et al.*, “Prevalence and factors associated with metabolic syndrome in an urban population of adults living with HIV in Nairobi, Kenya,” *PAMJ*. 2018; 2990, vol. 29, no. 90, Jan. 2018, doi: 10.11604/PAMJ.2018.29.90.13328.
- [45] P. D. M. C. Katoto *et al.*, “Prevalence and risk factors of metabolic syndrome in HIV-infected adults at three urban clinics in a post-conflict setting, eastern Democratic Republic of the Congo,” *Trop. Med. Int. Heal.*, vol. 23, no. 7, pp. 795–805, Jul. 2018, doi: 10.1111/TMI.13073.

- [46] N. Elmalaika Husain *et al.*, “Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten Background: The current challenge in managing people living with human immunodeficiency,” 2017, doi: 10.2147/HIV.S137974.
- [47] B. Jarwani, “Cardiovascular Disease and Antiretroviral Therapy,” *J. Glob. Infect. Dis.*, vol. 11, no. 3, p. 91, Jul. 2019, doi: 10.4103/JGID.JGID_4_18.
- [48] A. G. Vos and W. D. F. Venter, “Cardiovascular toxicity of contemporary antiretroviral therapy,” *Curr. Opin. HIV AIDS*, vol. 16, no. 6, pp. 286–291, Nov. 2021, doi: 10.1097/COH.0000000000000702.
- [49] C. Bavinger *et al.*, “Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review,” *PLoS One*, vol. 8, no. 3, p. e59551, Mar. 2013, doi: 10.1371/JOURNAL.PONE.0059551.
- [50] S. Krishnan *et al.*, “Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naïve HIV-infected individuals,” *J. Acquir. Immune Defic. Syndr.*, vol. 61, no. 3, p. 381, Nov. 2012, doi: 10.1097/QAI.0B013E3182690E3C.
- [51] A. Tadewos, Z. Addis, H. Ambachew, and S. Banerjee, “Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study,” *AIDS Res. Ther.*, vol. 9, no. 1, pp. 1–8, Oct. 2012, doi: 10.1186/1742-6405-9-31/TABLES/6.
- [52] E. W. Pefura Yone, A. F. Betyoumin, A. P. Kengne, F. J. Kaze Folefack, and J. Ngogang, “First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: A cross-sectional study,” *AIDS Res. Ther.*, vol. 8, no. 1, pp. 1–8, Sep. 2011, doi: 10.1186/1742-6405-8-33/FIGURES/2.
- [53] A. Kemal *et al.*, “Dyslipidemia and Associated Factors Among Adult Patients on Antiretroviral Therapy in Armed Force Comprehensive and Specialized Hospital, Addis Ababa, Ethiopia,” *HIV. AIDS. (Auckl)*, vol. 12, p. 221, 2020, doi: 10.2147/HIV.S252391.
- [54] E. N. Anyabolu, “Dyslipidemia in people living with HIV-AIDS in a tertiary hospital in South-East Nigeria,” *Pan Afr. Med. J.*, vol. 28, Nov. 2017, doi: 10.11604/PAMJ.2017.28.204.13505.
- [55] M. S. Obsa *et al.*, “Determinants of Dyslipidemia in Africa: A Systematic Review and Meta-Analysis,” *Front. Cardiovasc. Med.*, vol. 8, p. 2249, Feb. 2022, doi: 10.3389/FCVM.2021.778891.
- [56] A. Tilahun *et al.*, “Prevalence and predictors of dyslipidemia among HAART treated and HAART naïve HIV positive clients attending Debre Tabor Hospital, Debre Tabor, Ethiopia,” *Heliyon*, vol. 8, no. 11, p. e11342, Nov. 2022, doi: 10.1016/J.HELIYON.2022.E11342.
- [57] A. Amberbir *et al.*, “Dyslipidemia among rural and urban HIV patients in south-east Malawi,” *PLoS One*, vol. 13, no. 5, May 2018, doi: 10.1371/JOURNAL.PONE.0197728.
- [58] O. O. Achila *et al.*, “Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea,” *PLoS One*, vol. 17, no. 7, p. e0270838, Jul. 2022, doi: 10.1371/JOURNAL.PONE.0270838.

- [59] B. Omech *et al.*, “Prevalence of HIV-Associated Metabolic Abnormalities among Patients Taking First-Line Antiretroviral Therapy in Uganda,” *ISRN AIDS*, vol. 2012, pp. 1–6, 2012, doi: 10.5402/2012/960178.
- [60] J. J. Bigna *et al.*, “Global burden of hypertension among people living with HIV in the era of increased life expectancy: a systematic review and meta-analysis,” *J. Hypertens.*, vol. 38, no. 9, pp. 1659–1668, Sep. 2020, doi: 10.1097/HJH.0000000000002446.
- [61] J. Okyere, C. Ayebeng, B. A. Owusu, and K. S. Dickson, “Prevalence and factors associated with hypertension among older people living with HIV in South Africa,” *BMC Public Health*, vol. 22, no. 1, pp. 1–9, Dec. 2022, doi: 10.1186/S12889-022-14091-Y/TABLES/2.
- [62] D. Harimenshi, T. Niyongabo, P. M. Preux, V. Aboynans, and I. Desormais, “Hypertension and associated factors in HIV-infected patients receiving antiretroviral treatment in Burundi: a cross-sectional study,” *Sci. Reports 2022* 121, vol. 12, no. 1, pp. 1–8, Nov. 2022, doi: 10.1038/s41598-022-24997-7.
- A. A. Adedimeji *et al.*, “Trends in demographic and clinical characteristics and initiation of antiretroviral therapy among adult patients enrolling in HIV care in the Central Africa International epidemiology Database to Evaluate AIDS (CA-IeDEA) 2004 to 2018,” *J. Int. AIDS Soc.*, vol. 24, no. 6, p. e25672, Jun. 2021, doi: 10.1002/JIA2.25672.
- [64] N. Chiwandire, N. Zungu, M. Mabaso, and C. Chasela, “Trends, prevalence and factors associated with hypertension and diabetes among South African adults living with HIV, 2005–2017,” *BMC Public Health*, vol. 21, no. 1, pp. 1–14, 2021, doi: 10.1186/s12889-021-10502-8.
- [65] B. T. Zewudie *et al.*, “The magnitude of undiagnosed hypertension and associated factors among HIV-positive patients attending antiretroviral therapy clinics of Butajira General Hospital, Gurage Zone, Southern Ethiopia,” *SAGE Open Med.*, vol. 10, no. X, p. 205031212210944, 2022, doi: 10.1177/20503121221094454.
- [66] C. U. Nduka, S. Stranges, A. M. Sarki, P. K. Kimani, and O. A. Uthman, “Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis,” *J. Hum. Hypertens.*, vol. 30, no. 6, pp. 355–362, Jun. 2016, doi: 10.1038/JHH.2015.97.
- [67] R. Palacios Muñoz *et al.*, “Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients,” *HIV Med.*, vol. 7, no. 1, pp. 10–15, Jan. 2006, doi: 10.1111/J.1468-1293.2005.00333.X.
- [68] Brown, T.T.; Cole, S.R.; Li, X.; Kingsley, L.A.; Palella, F.J.; Riddler, S.A.; Visscher, B.R.; Margolick, J.B.; Dobs, A.S. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. *Arch. Intern. Med.* **2005**, *165*, 1179–1184.
- [69] Galli, L.; Salpietro, S.; Pellicciotta, G.; Galliani, A.; Piatti, P.; Hasson, H.; Guffanti, M.; Gianotti, N.; Bigoloni, A.; Lazzarin, A.; et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. *Eur. J. Epidemiol.* **2012**, *27*, 657–665
- [70] Prioreshi, A.; Munthali, R.; Soepnel, L.; A Goldstein, J.; Micklesfield, L.; Aronoff, D.; Norris, S. Incidence and prevalence of type 2 diabetes mellitus with HIV infection in Africa: A systematic review and meta-analysis. *BMJ Open* **2017**, *7*, e013953.

- [71] Butt, A.A.; McGinnis, K.; Rodriguez-Barradas, M.C.; Crystal, S.; Simberkoff, M.; Goetz, M.; Leaf, D.; Justice, A.C. HIV infection and the risk of diabetes mellitus. *AIDS* **2009**, *23*, 1227–1234.
- [72] Hsue PY, Joan CL, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima media thickness in patients with HIV infections. *Circulation*. 2004;109:1603–1608.
- [73] Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. *AIDS*. 2000;14:123–128.
- [74] David MH, Hornung R, Fichtenbaum JC. Ischemic cardiovascular disease in persons with human immunodeficiency virus infections. *Clin Infect Dis*. 2002;34:98–102.
- [75] H. O. T. Pambou *et al.*, “Assessment of cardiovascular risk factors among HIV-infected patients aged 50 years and older in Cameroon,” *AIMS Public Heal.*, vol. 9, no. 3, pp. 490–505, 2022, doi: 10.3934/PUBLICHEALTH.2022034.
- [76] F. Mashinya, M. Alberts, J. P. Van geertruyden, and R. Colebunders, “Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: A cross sectional study,” *AIDS Res. Ther.*, vol. 12, no. 1, pp. 1–10, Dec. 2015, doi: 10.1186/S12981-015-0083-6/TABLES/3.
- [77] M. Nyirenda, “Assessment of cardiovascular disease risks using Framingham risk scores (FRS) in HIV-positive and HIV-negative older adults in South Africa,” *Prev. Med. Reports*, vol. 22, p. 101352, Jun. 2021, doi: 10.1016/J.PMEDR.2021.101352.
- [78] A. C. Achhra *et al.*, “Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations,” *Curr. HIV/AIDS Rep.*, vol. 18, no. 4, p. 271, Aug. 2021, doi: 10.1007/S11904-021-00567-W.
- [79] D. D. Bosho, L. Dube, T. A. Mega, D. A. Adare, M. G. Tesfaye, and T. C. Eshetie, “Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV),” *Diabetol. Metab. Syndr.*, vol. 10, no. 1, pp. 1–9, Feb. 2018, doi: 10.1186/S13098-018-0312-Y/TABLES/4.
- [80] M. N. Pedro *et al.*, “Insulin Resistance in HIV-Patients: Causes and Consequences,” *Frontiers in Endocrinology*, vol. 9, no. SEP. Frontiers Media S.A., p. 514, Sep. 05, 2018, doi: 10.3389/fendo.2018.00514.

Figure 1. Enrollment schema for the GLUMED study.




Table 1. Baseline characteristics of PWH by sex before ART initiation (N=309)

Characteristics	All PWH	Male	Female	p-Value
Total	309	126	183	
Age, years				
Median (IQR)	31 (27-39)	34 (28-40)	30 (26-37)	<0.001
< 30	122 (39.5)	35 (27.8)	87 (47.5)	0.002
30-39	121 (39.2)	57 (45.2)	64 (35.0)	
40-49	57 (18.4)	31 (24.6)	26 (14.2)	
≥50	9 (2.9)	3 (2.4)	6 (3.3)	
Relationship status				
Single	178 (57.6)	62 (49.2)	116 (63.4)	0.013
Married	131 (42.4)	64 (50.8)	67 (36.6)	
Education				
None	4 (1.3)	0	4 (2.2)	0.015
Primary	166 (53.7)	74 (58.7)	92 (50.3)	
Secondary	126 (40.8)	43 (34.2)	83 (45.4)	
Tertiary	13 (4.2)	9 (7.1)	4 (2.1)	
Religion				
Christian	245 (79.3)	102 (81.0)	143 (78.1)	0.549
Muslim	64 (20.7)	24 (19.0)	40 (21.9)	
Residence				
Urban	285 (92.2)	120 (95.2)	165 (90.2)	0.101
Rural	24 (7.8)	6 (4.8)	18 (9.8)	
Employment				
Yes	253 (81.9)	120 (95.2)	133 (72.7)	<0.001
No	56 (18.1)	6 (4.8)	50 (27.3)	
Baseline CD4 count, cells/mm³ (n=259)				
Median (IQR)	318 (163-550)	251 (123-382)	399 (238-6510)	<0.001
≤99	36 (13.9)	21 (20.4)	15 (9.6)	<0.001
100-199	37 (14.3)	21 (20.4)	16 (10.3)	
200-349	66 (25.5)	31 (30.1)	35 (22.4)	
≥350	120 (46.3)	30 (29.1)	90 (57.7)	

Table 2. Cardiometabolic risk factors by sex in PWH prior to ART initiation

Risk factors	All PWH	Male	Female	p-Value
Total	309	126	183	
Active or past smoking				
Yes	15 (4.9)	9 (7.1)	6 (3.3)	0.120
No	294 (95.1)	117 (92.9)	177 (96.7)	
Alcohol use (AUDIT scores)				
0-7 (low-risk)	263 (85.1)	97 (77.0)	166 (90.7)	0.011
8-15 (at risk)	26 (8.4)	16 (12.7)	10 (5.5)	
16-19 (high risk)	12 (3.9)	8 (6.3)	4 (2.2)	
≥20 (addiction)	8 (2.6)	5 (4.0)	3 (1.6)	
Level of physical activity				
<600 MET (does not meet WHO goals)	68 (22.0)	22 (17.5)	46 (25.1)	0.109
≥600 MET (meets WHO goals)	241 (78.0)	104 (82.5)	137 (74.9)	
Body mass index, kg/m²				
Median (IQR)	22.2 (19.7-25.6)	21.1 (19.2-22.9)	23.4 (20.7-27.6)	<0.001
<18.5 (underweight)	32 (10.4)	16 (12.7)	16 (8.78)	<0.001
18.5-24.9 (normal)	185 (59.9)	96 (76.2)	89 (48.6)	
25.0-29.9 (pre-obesity)	67(21.7)	10 (7.9)	57 (31.1)	
≥30 (obese)	25 (8.1)	4 (3.2)	21 (11.5)	
Waist circumference, cm				
Median (IQR)	79.0 (75.0-86.0)	79.0 (75.0-83.0)	81.0 (74.0-88.0)	0.153
Not at risk (males: <95 cm and females: <81 cm)	204 (66.0)	115 (91.3)	89 (48.6)	<0.001
Increased risk (males: ≥95 to ≤102 cm and females: ≥81 to ≤88 cm)	57 (18.4)	8 (6.3)	49 (26.8)	
Substantially increased risk (males: ≥ 103 cm and females: ≥89 cm)	48 (15.5)	3 (2.4)	45 (24.6)	
Blood pressure, mmHG				
Normal (<120/80 mmHg)	232 (75.1)	92 (73.0)	140 (76.5)	0.115
Pre-hypertension (120-139/80-89 mmHg)	52 (16.8)	19 (15.1)	33 (18.0)	
Hypertension (≥ 140/90 mmHg)	25 (8.1)	15 (11.9)	10 (5.5)	
Laboratory-based CVD risk score * (n=170)				
<5%	149 (87.6)	67 (79.8)	82 (95.3)	0.007
5-10%	18 (10.6)	15 (17.9)	3 (3.5)	
>10%	3 (1.8)	2 (2.4)	1 (1.2)	
Blood glucose, mg/dL				

Normal (fasting < 100 mg/dL or 2-hour OGGT <140 mg/dL)	252 (81.6)	98 (77.8)	154 (84.2)	0.150
Prediabetes (fasting 100-125 mg/dL or 2-hour glucose 140-199 mg/dL)	56 (18.1)	27 (21.4)	29 (15.8)	
Diabetes (fasting ≥ 126 mg/dL or 2-hour or glucose ≥ 200 mg/dL)	1 (0.3)	1 (0.8)	0 (0)	
Serum creatinine, mg/dL (n=281)				
Median (IQR)	0.80 (0.68-0.93)	0.89 (0.77-1.01)	0.76 (0.64-0.84)	<0.001
eGFR, ml/min/1.73m² (n=281)				
Median, IQR	111 (96-129)	118 (99-135)	106 (94-122)	0.231
≥90 (Stage 1)	230 (81.9)	101 (86.3)	129 (78.7)	
60-89 (Stage 2)	47 (16.7)	14 (12.0)	33 (20.1)	
45-59 (Stage 3a)	2 (0.7)	1 (0.9)	1 (0.6)	
30-44 (Stage 3b)	2 (0.7)	1(0.9)	1 (0.6)	
29-15 (Stage 4)	0 (0)	0 (0)	0 (0)	
<15 (Stage 5)	0 (0)	0 (0)	0 (0)	
Total cholesterol (TC), mg/dL (n=282)				
Median, IQR	132 (112-157)	125 (106-147)	138 (115-163)	0.002
TC > 200 mg/dL	15 (5.3)	4 (3.4)	11 (6.7)	0.288
HDL-C, mg/dL (n=282)				
Median, IQR	31 (24-38)	27 (22-36)	34 (26-41)	<0.001
HDL-C < 40 mg/dL	249 (88.3)	101 (86.3)	148 (89.7)	
LDL-C, mg/dL (n=282)				
Median, IQR	73 (53-93)	66 (50-88)	78 (56-100)	0.007
LDL-C > 100 mg/dL	59 (20.9)	14 (12.0)	45 (27.3)	0.002
Triglycerides (TG) mg/dL (n=282)				
Median, IQR	89 (62-118)	93 (70-124)	86 (59-116)	0.058
TG > 150 mg/dL	37 (13.1)	19 (16.2)	18 (10.9)	0.191
Dyslipidemia^a (any 1 of the following: elevated TC^b, low HDL-C^c, elevated LDL-C^d or elevated TG^e) (n=282)				
Yes	264 (93.6)	106 (90.6)	158 (95.8)	0.081
No	18 (6.4)	11 (9.4)	7 (4.2)	
Metabolic syndrome (any 3 of the following: central obesity^f, elevated fasting blood glucose^g, HTN^g, low HDL-C^c or elevated TG^e)				
Yes	43 (13.9)	13 (10.3)	30 (16.4)	0.129
No	266 (86.1)	113 (89.7)	153 (3.6)	

*- calculated by the laboratory-based Framingham risk score, b- Total cholesterol, c- High density lipoproteins, d- Low density lipoproteins, e- Triglycerides, f- , g-, h

Table 3. Predictors of the MetS and its components in PWH prior to ART initiation

Risk factors	Metabolic syndrome		Hypertension		Dyslipidemia		Hyperglycemia	
	OR (95%CI)	AOR (95% CI)	OR (95%CI)	AOR (95% CI)	OR (95%CI)	AOR (95% CI)	OR (95%CI)	AOR (95% CI)
Gender								
Male	Ref	Ref	Ref	Ref	Ref	Ref	Ref	
Female	1.70 (0.85-3.41)	1.44 (0.64-3.25)	0.61 (0.33-1.11)	0.58 (0.24-1.41)	2.34 (0.88-6.25)	1.56 (0.51-4.77)	0.76 (0.36-1.58)	
Age, years								
< 40	Ref	Ref	Ref	Ref	Ref		Ref	Ref
≥ 40	3.27 (1.65-6.47)	3.33 (1.45-7.67)**	2.67 (1.39-5.10)	2.96 (1.32-6.64)***	0.96 (0.31-3.04)		1.79 (0.80-4.00)	1.59 (0.70-3.59)
Relationship status								
Single	Ref		Ref		Ref		Ref	
Married	1.35 (0.71-2.58)		1.25 (0.69-2.29)		0.57 (0.22-1.49)		0.92 (0.44-1.94)	
Education								
Primary or less	Ref		Ref	Ref	Ref		Ref	
Secondary/tertiary	1.07 (0.56-2.05)		1.62 (0.87-3.02)	1.61 (0.77-3.33)	1.01 (0.39-2.64)		1.41 (0.66-2.99)	
Religion								
Christian	1.40 (0.59-3.32)		1.49 (0.66-3.35)		0.46 (0.10-2.08)		0.76 (0.32-1.78)	
Muslim	Ref		Ref		Ref		Ref	
Residence								
Urban	1.14 (0.33-4.01)		0.73 (0.26-2.06)		4.43 (1.31-15.01)	4.99 (1.35-18.53)***	0.79 (0.22-2.82)	
Rural	Ref		Ref		Ref	Ref	Ref	
Employment								

Yes	1.43 (0.57-3.57)		2.27 (0.86-5.99)	1.41 (0.49-4.08)	0.25 (0.03-1.94)	0.31 (0.04-2.62)	3.63 (0.84-15.67)	3.55 (0.81-15.51)
No	Ref		Ref	Ref	Ref	Ref	Ref	Ref
Smoking								
Yes	1.59 (0.43-5.87)		1.28 (0.35-4.71)		0.74 (0.09-6.07)		-	
No	Ref		Ref		Ref			
Alcohol use (AUDIT scores)								
Low-moderate	Ref		Ref		Ref		Ref	
High risk	0.67 (0.15-3.01)		0.54 (0.12-2.42)		0.59 (0.13-2.75)		0.96 (0.21-4.34)	
Physical activity								
High	Ref		Ref		Ref		Ref	
Low	0.92 (0.43-1.98)		0.90 (0.44-1.83)		1.44 (0.40-5.14)		1.45 (0.64-3.29)	
Body mass index, kg/m²								
<25	-	-	Ref	Ref	Ref	Ref	Ref	Ref
≥25	-	-	2.25 (1.21-4.17)	2.94 (0.83-10.43)	7.93 (1.04-60.61)	6.29 (0.48-81.57)	1.72 (0.81-3.68)	1.78 (0.83-3.81)
Waist circumference								
Normal	-	-	Ref	Ref	Ref	Ref	Ref	
Increased	-	-	1.57 (0.85-2.90)	1.16 (0.32-4.35)	4.63 (1.05-20.64)	1.03 (0.14-7.45)	1.00 (0.46-2.17)	
CD count cells/mm³								
<200	Ref	Ref	Ref	Ref	Ref		Ref	
≥200	3.32 (1.13-9.78)	3.79 (1.23-11.63)***	2.50 (1.00-6.23)	2.90 (1.09-7.73)**	0.62(0.17-2.26)		1.01 (0.40-2.53)	

Variables that were found to be significant, <.20 in univariable and <.05 in multivariable, are marked in bold.

Significance p-levels:

**p <0.05.

***p <0.01.